Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

Here are some of the recent management changes that took place during the week: Biogen (NASDAQ:BIIB) said its Executive Vice ...

US Bancorp DE reduced its stake in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 15.7% in the third quarter, according ...

Biogen (NASDAQ: BIIB) Q3 2024 Earnings Call Oct 30, 2024, 8:30 a.m. ET ...

In a report released today, Mohit Bansal from Wells Fargo maintained a Hold rating on Biogen (BIIB – Research Report), with a price ...

Biogen's Q3 earnings report shows flat growth but highlights its value for risk-tolerant investors in CNS disease treatment.

Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Ballentine Partners LLC lowered its stake in Biogen Inc. (NASDAQ:BIIB – Free Report) by 54.1% in the 3rd quarter, according ...

Biogen partners with Neomorph to develop molecular glue degraders for Alzheimer's and other diseases, offering up to $1.45B in payments.

Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on Biogen (BIIB – Research Report) today and set a price target of ...

Biogen expects annual adjusted profit per share of $16.10 to $16.60, compared with a $15.75 to $16.25 per-share range ...